‘Tiltan Pharma’ Starts Phase II Trial For Pancreatic Cancer Drug
Tiltan Pharma Ltd. announced it has started phase II of its clinical trial for its new drug for pancreatic cancer, following approval by the Israeli Ministry of Health. The drug is designed to prevent blood flow to tumors and prevent their growth. The second phase of the trial will include 80 patients: 40 with newly […]
February 16, 2012